

References

- [1] J. Bicker, G. Alves, A. Fortuna, A. Falcão, Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review, *European Journal of Pharmaceutics and Biopharmaceutics*, 87 (2014) 409-432.
- [2] F. Zhang, C.-L. Xu, C.-M. Liu, Drug delivery strategies to enhance the permeability of the blood–brain barrier for treatment of glioma, *Drug Design, Development and Therapy*, 9 (2015) 2089-2100.
- [3] L. Saenz del Burgo, R.M. Hernández, G. Orive, J.L. Pedraz, Nanotherapeutic approaches for brain cancer management, *Nanomedicine: Nanotechnology, Biology and Medicine*, 10 (2014) e905-e919.
- [4] J. Clarke, N. Butowski, S. Chang, REcent advances in therapy for glioblastoma, *Archives of Neurology*, 67 (2010) 279-283.
- [5] M. Takaoka, The Phenolic Substances of white Hellebore (*Veratrum Grandiflorum* Loes fil.) II Oxyresveratrol, *Nippon Kagaku Kaishi*, 60 (1939) 1261-1264.
- [6] S. Nonomura, H. Kanagawa, A. Makimoto, Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-JO-Kon. (*Polygonum Cuspidatum* Sieb. Et Zucc.), *Yakugaku Zasshi*, 83 (1963) 988-990.
- [7] J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence, *Nature reviews. Drug Discovery*, 5 (2006) 493-506.

- [8] W. Zhang, Z. Fei, H.N. Zhen, J.N. Zhang, X. Zhang, Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells, *Journal of Neuro-oncology*, 81 (2007) 231-240.
- [9] H. Jiang, L. Zhang, J. Kuo, K. Kuo, S.C. Gautam, L. Groc, A.I. Rodriguez, D. Koubi, T. Jackson Hunter, G.B. Corcoran, M.D. Seidman, R.A. Levine, Resveratrol-induced apoptotic death in human U251 glioma cells, *Molecular Cancer Therapeutics*, 4 (2005) 554-561.
- [10] N. Gagliano, C. Moscheni, C. Torri, I. Magnani, A.A. Bertelli, M. Gioia, Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and Secreted Protein Acidic and Rich in Cysteine (SPARC) on human cultured glioblastoma cells, *Biomedicine & Pharmacotherapy, Biomedecine & Pharmacotherapie*, 59 (2005) 359-364.
- [11] N. Gagliano, G. Aldini, G. Colombo, R. Rossi, R. Colombo, M. Gioia, A. Milzani, I. Dalle-Donne, The potential of resveratrol against human gliomas, *Anti-cancer Drugs*, 21 (2010) 140-150.
- [12] S. Leone, M. Fiore, M.G. Lauro, S. Pino, T. Cornetta, R. Cozzi, Resveratrol and X rays affect gap junction intercellular communications in human glioblastoma cells, *Molecular Carcinogenesis*, 47 (2008) 587-598.
- [13] S.H. Tseng, S.M. Lin, J.C. Chen, Y.H. Su, H.Y. Huang, C.K. Chen, P.Y. Lin, Y. Chen, Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats, *Clinical Cancer Research*, 10 (2004) 2190-2202.

- [14] M. Emília Juan, J. Buenafuente, I. Casals, J.M. Planas, Plasmatic levels of trans-resveratrol in rats, *Food Research International*, 35 (2002) 195-199.
- [15] A. Amri, J.C. Chaumeil, S. Sfar, C. Charrueau, Administration of resveratrol: What formulation solutions to bioavailability limitations?, *Journal of Controlled Release*, 158 (2012) 182-193.
- [16] T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis, Jr., U.K. Walle, High absorption but very low bioavailability of oral resveratrol in humans, *Drug Metabolism and Disposition: the Biological Fate of Chemicals*, 32 (2004) 1377-1382.
- [17] H. Colom, I. Alfaras, M. Maijo, M.E. Juan, J.M. Planas, Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats, *Pharmaceutical Research*, 28 (2011) 1606-1621.
- [18] J.F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.P. Moreau, M.P. Ducharme, Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model, *The Journal of Pharmacology and Experimental Therapeutics*, 302 (2002) 369-373.
- [19] L. Mu, S.S. Feng, A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS, *Journal of Controlled Release*, 86 (2003) 33-48.

- [20] M.S. Muthu, S.A. Kulkarni, J. Xiong, S.S. Feng, Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells, *International Journal of Pharmaceutics*, 421 (2011) 332-340.
- [21] A. Raju, M.S. Muthu, S.S. Feng, Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel, *Expert Opinion on Drug Delivery*, 10 (2013) 747-760.
- [22] Z. Zhang, S. Tan, S.S. Feng, Vitamin E TPGS as a molecular biomaterial for drug delivery, *Biomaterials*, 33 (2012) 4889-4906.
- [23] K. Manjunath, J.S. Reddy, V. Venkateswarlu, Solid lipid nanoparticles as drug delivery systems, *Methods and Findings in Experimental and Clinical Pharmacology*, 27 (2005) 127-144.
- [24] V.S. Shenoy, I.K. Vijay, R.S. Murthy, Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles, *The Journal of Pharmacy and Pharmacology*, 57 (2005) 411-422.
- [25] Y. Sheng, L. Chang, T. Kuang, J. Hu, PEG/heparin-decorated lipid-polymer hybrid nanoparticles for long-circulating drug delivery, *RSC Advances*, 6 (2016) 23279-23287.
- [26] L.E. van Vlerken, Z. Duan, S.R. Little, M.V. Seiden, M.M. Amiji, Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model, *Molecular Pharmaceutics*, 5 (2008) 516-526.

- [27] F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, V. Preat, PLGA-based nanoparticles: an overview of biomedical applications, *Journal of Controlled Release*, 161 (2012) 505-522.
- [28] M. Azizi, F. Farahmandghavi, M. Joghataei, M. Zandi, M. Imani, M. Bakhtiary, F.A. Dorkoosh, F. Ghazizadeh, Fabrication of protein-loaded PLGA nanoparticles: effect of selected formulation variables on particle size and release profile, *Journal of Polymer Research*, 20 (2013) 110.
- [29] H.K. Makadia, S.J. Siegel, Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier, *Polymers*, 3 (2011) 1377-1397.
- [30] P.N. Gupta, S. Jain, C. Nehate, N. Alam, V. Khare, R.D. Dubey, A. Saneja, S. Kour, S.K. Singh, Development and evaluation of paclitaxel loaded PLGA:poloxamer blend nanoparticles for cancer chemotherapy, *International Journal of Biological Macromolecules*, 69 (2014) 393-399.
- [31] Y. Fan, Q. Zhang, Development of liposomal formulations: From concept to clinical investigations, *Asian Journal of Pharmaceutical Sciences*, 8 (2013) 81-87.
- [32] L. Guo, L. Fan, Z. Pang, J. Ren, Y. Ren, J. Li, J. Chen, Z. Wen, X. Jiang, TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes, *Journal of Controlled Release*, 154 (2011) 93-102.

- [33] T. Siegal, A. Horowitz, A. Gabizon, Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy, *Journal of Neurosurgery*, 83 (1995) 1029-1037.
- [34] D. Vllasaliu, R. Fowler, S. Stolnik, PEGylated nanomedicines: recent progress and remaining concerns, *Expert Opinion on Drug Delivery*, 11 (2014) 139-154.
- [35] J. Bai, Z. Zhou, H. Tang, S. Song, J. Peng, Y. Xu, Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA, *Journal of Liposome Research*, 23 (2013) 1-10.
- [36] L.M. Hung, M.J. Su, J.K. Chen, Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms, *Free radical Biology & Medicine*, 36 (2004) 774-781.
- [37] G. Bozzuto, A. Molinari, Liposomes as nanomedical devices, *International Journal of Nanomedicine*, 10 (2015) 975-999.
- [38] J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, *International Journal of Cancer*, 127 (2010) 2893-2917.
- [39] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, *International Journal of Cancer*, 136 (2015) E359-386.

- [40] S. Bradamante, L. Barenghi, F. Piccinini, A.A.E. Bertelli, R. De Jonge, P. Beemster, J.W. De Jong, Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism, *European Journal of Pharmacology*, 465 (2003) 115-123.
- [41] M. Floreani, E. Napoli, L. Quintieri, P. Palatini, Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity, *Life Sciences*, 72 (2003) 2741-2750.
- [42] P.S. Ray, G. Maulik, G.A. Cordis, A.A. Bertelli, A. Bertelli, D.K. Das, The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury, *Free radical Biology & Medicine*, 27 (1999) 160-169.
- [43] M. Sato, P.S. Ray, G. Maulik, N. Maulik, R.M. Engelman, A.A. Bertelli, A. Bertelli, D.K. Das, Myocardial protection with red wine extract, *Journal of Cardiovascular Pharmacology*, 35 (2000) 263-268.
- [44] L.-M. Hung, M.-J. Su, W.-K. Chu, C.-W. Chiao, W.-F. Chan, J.-K. Chen, The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy, *British Journal of Pharmacology*, 135 (2002) 1627-1633.
- [45] S. Renaud, R. Gueguen, The French paradox and wine drinking, *Novartis Foundation symposium*, 216 (1998) 208-217; Discussion 217-222, 152-208.

- [46] S. Renaud, M. de Lorgeril, Wine, alcohol, platelets, and the French paradox for coronary heart disease, *Lancet* (London, England), 339 (1992) 1523-1526.
- [47] J.L. Richard, [Coronary risk factors. The French paradox], *Archives Des Maladies Du Coeur et Des Vaisseaux*, 80 Spec No (1987) 17-21.
- [48] D.F. Fitzpatrick, S.L. Hirschfield, R.G. Coffey, Endothelium-dependent vasorelaxing activity of wine and other grape products, *The American Journal of Physiology*, 265 (1993) H774-778.
- [49] J. Lekakis, L.S. Rallidis, I. Andreadou, G. Vamvakou, G. Kazantzoglou, P. Magiatis, A.L. Skaltsounis, D.T. Kremastinos, Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease, *European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology*, 12 (2005) 596-600.
- [50] M. Seigneur, J. Bonnet, B. Dorian, D. Benchimol, F. Drouillet, G. Gouverneur, J. Larrue, R. Crockett, M.R. Boisseau, P. Ribereau-Gayon, H. Bricaud, Effect of the consumption of alcohol, white wine, and red wine on platelet function and serum lipids, *Journal of Applied Cardiology*, 5 (1990) 215-222.
- [51] H.S. Demrow, P.R. Slane, J.D. Folts, Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries, *Circulation*, 91 (1995) 1182-1188.

- [52] Z. Wang, J. Zou, K. Cao, T.C. Hsieh, Y. Huang, J.M. Wu, Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels, *International Journal of Molecular Medicine*, 16 (2005) 533-540.
- [53] M. Gronbaek, A. Deis, T.I. Sorensen, U. Becker, P. Schnohr, G. Jensen, Mortality associated with moderate intakes of wine, beer, or spirits, *BMJ (Clinical Research Edition)*, 310 (1995) 1165-1169.
- [54] M. Bohm, S. Rosenkranz, U. Laufs, Alcohol and red wine: impact on cardiovascular risk, *Nephrology, Dialysis, Transplantation*, 19 (2004) 11-16.
- [55] A.A. Bertelli, L. Giovannini, D. Giannessi, M. Migliori, W. Bernini, M. Fregoni, A. Bertelli, Antiplatelet activity of synthetic and natural resveratrol in red wine, *International Journal of Tissue Reactions*, 17 (1995) 1-3.
- [56] Z. Wang, Y. Huang, J. Zou, K. Cao, Y. Xu, J.M. Wu, Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro, *International Journal of Molecular Medicine*, 9 (2002) 77-79.
- [57] D. Miura, Y. Miura, K. Yagasaki, Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats, *Life Sciences*, 73 (2003) 1393-1400.

- [58] M.S. Muthu, S.A. Kulkarni, A. Raju, S.S. Feng, Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots, *Biomaterials*, 33 (2012) 3494-3501.
- [59] K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, J.G. Wood, R.E. Zipkin, P. Chung, A. Kisielewski, L.L. Zhang, B. Scherer, D.A. Sinclair, Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan, *Nature*, 425 (2003) 191-196.
- [60] K. Sinha, G. Chaudhary, Y.K. Gupta, Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats, *Life Sciences*, 71 (2002) 655-665.
- [61] Q. Wang, J. Xu, G.E. Rottinghaus, A. Simonyi, D. Lubahn, G.Y. Sun, A.Y. Sun, Resveratrol protects against global cerebral ischemic injury in gerbils, *Brain Research*, 958 (2002) 439-447.
- [62] Y.J. Wang, F. He, X.L. Li, The neuroprotection of resveratrol in the experimental cerebral ischemia, *Zhonghua Yi Xue Za Zhi*, 83 (2003) 534-536.
- [63] R.A. Roberts, D.L. Laskin, C.V. Smith, F.M. Robertson, E.M. Allen, J.A. Doorn, W. Slikker, Nitrate and oxidative stress in toxicology and disease, *Toxicological Sciences*, 112 (2009) 4-16.

- [64] H. Kaneto, N. Katakami, M. Matsuhisa, T.A. Matsuoka, Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis, *Mediators of Inflammation*, 2010 (2010) 453892.
- [65] J. Ciencewicki, S. Trivedi, S.R. Kleeberger, Oxidants and the pathogenesis of lung diseases, *The Journal of Allergy and Clinical Immunology*, 122 (2008) 456-468; quiz 469-470.
- [66] S.V. Nigdikar, N.R. Williams, B.A. Griffin, A.N. Howard, Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo, *The American Journal of Clinical Nutrition*, 68 (1998) 258-265.
- [67] H. Ghanim, C.L. Sia, K. Korzeniewski, T. Lohano, S. Abuaysheh, A. Marumganti, A. Chaudhuri, P. Dandona, A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal, *The Journal of Clinical Endocrinology and Metabolism*, 96 (2011) 1409-1414.
- [68] M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver, J. Auwerx, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, *Cell*, 127 (2006) 1109-1122.
- [69] C. Sun, F. Zhang, X. Ge, T. Yan, X. Chen, X. Shi, Q. Zhai, SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B, *Cell Metabolism*, 6 (2007) 307-319.

[70] T. Yoshizaki, S. Schenk, T. Imamura, J.L. Babendure, N. Sonoda, E.J. Bae, D.Y. Oh, M. Lu, J.C. Milne, C. Westphal, G. Bandyopadhyay, J.M. Olefsky, SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity, *American journal of physiology. Endocrinology and Metabolism*, 298 (2010) E419-428.

[71] J.A. Baur, K.J. Pearson, N.L. Price, H.A. Jamieson, C. Lerin, A. Kalra, V.V. Prabhu, J.S. Allard, G. Lopez-Lluch, K. Lewis, P.J. Pistell, S. Poosala, K.G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K.W. Fishbein, R.G. Spencer, E.G. Lakatta, D. Le Couteur, R.J. Shaw, P. Navas, P. Puigserver, D.K. Ingram, R. de Cabo, D.A. Sinclair, Resveratrol improves health and survival of mice on a high-calorie diet, *Nature*, 444 (2006) 337-342.

[72] J.M. Smoliga, J.A. Baur, H.A. Hausenblas, Resveratrol and health--a comprehensive review of human clinical trials, *Molecular Nutrition and Food Research*, 55 (2011) 1129-1141.

[73] P. Brasnyo, G.A. Molnar, M. Mohas, L. Marko, B. Laczy, J. Cseh, E. Mikolas, I.A. Szijarto, A. Merei, R. Halmai, L.G. Meszaros, B. Sumegi, I. Wittmann, Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients, *The British Journal of Nutrition*, 106 (2011) 383-389.

[74] E.K. Naderali, P.J. Doyle, G. Williams, Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs, *Clinical Science*, 98 (2000) 537.

[75] U. Jager, H. Nguyen-Duong, Relaxant effect of trans-resveratrol on isolated porcine coronary arteries, *Arzneimittel-Forschung*, 49 (1999) 207-211.

- [76] H. Arichi, Y. Kimura, H. Okuda, K. Baba, M. Kozawa, S. Arichi, Effects of stilbene components of the roots of *Polygonum cuspidatum* Sieb. et Zucc. on lipid metabolism, *Chemical and Pharmaceutical Bulletin*, 30 (1982) 1766-1770.
- [77] P. Kollar, H. Kotolova, J. Necas, M. Karpisek, L. Bartosikova, P. Karesova, [Experimental study of resveratrol and flavonoids in red wine with regard to their possible hypolipemic effects], *Vnitřní Lekarství*, 46 (2000) 856-860.
- [78] M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, J.M. Pezzuto, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, *Science (New York)*, 275 (1997) 218-220.
- [79] L. Tessitore, A. Davit, I. Sarotto, G. Caderni, Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression, *Carcinogenesis*, 21 (2000) 1619-1622.
- [80] Y. Chen, S.H. Tseng, H.S. Lai, W.J. Chen, Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice, *Surgery*, 136 (2004) 57-66.
- [81] C.-J. Lin, C.-C. Lee, Y.-L. Shih, T.-Y. Lin, S.-H. Wang, Y.-F. Lin, C.-M. Shih, Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy, *Free Radical Biology and Medicine*, 52 (2012) 377-391.

- [82] X. Lu, C. Ji, H. Xu, X. Li, H. Ding, M. Ye, Z. Zhu, D. Ding, X. Jiang, X. Ding, X. Guo, Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress, *International Journal of Pharmaceutics*, 375 (2009) 89-96.
- [83] W. Guo, A. Li, Z. Jia, Y. Yuan, H. Dai, H. Li, Transferrin modified PEG-PLA-resveratrol conjugates: In vitro and in vivo studies for glioma, *European Journal of Pharmacology*, 718 (2013) 41-47.
- [84] K. Teskac, J. Kristl, The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol, *International Journal of Pharmaceutics*, 390 (2010) 61-69.
- [85] J. Shao, X. Li, X. Lu, C. Jiang, Y. Hu, Q. Li, Y. You, Z. Fu, Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels, *Colloids and Surfaces. B, Biointerfaces*, 72 (2009) 40-47.
- [86] B. Carletto, J. Berton, T.N. Ferreira, L.F. Dalmolin, K.S. Paludo, R.M. Mainardes, P.V. Farago, G.M. Favero, Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth, *Colloids and Surfaces. B, Biointerfaces*, 144 (2016) 65-72.
- [87] G. Singh, R.S. Pai, Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential, *Expert Opinion on Drug Delivery*, 11 (2014) 647-659.
- [88] V. Sanna, I.A. Siddiqui, M. Sechi, H. Mukhtar, Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene

glycol) blend for prostate cancer treatment, *Molecular Pharmaceutics*, 10 (2013) 3871-3881.

[89] L. Bu, L.C. Gan, X.Q. Guo, F.Z. Chen, Q. Song, Z. Qi, X.J. Gou, S.X. Hou, Q. Yao, Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma, *International Journal of Pharmaceutics*, 452 (2013) 355-362.

[90] F. Figueiro, A. Bernardi, R.L. Frozza, T. Terroso, A. Zanotto-Filho, E.H. Jandrey, J.C. Moreira, C.G. Salbego, M.I. Edelweiss, A.R. Pohlmann, S.S. Guterres, A.M. Battastini, Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in vivo glioma growth, *Journal of Biomedical Nanotechnology*, 9 (2013) 516-526.

[91] R.L. Frozza, A. Bernardi, K. Paese, J.B. Hoppe, T. da Silva, A.M. Battastini, A.R. Pohlmann, S.S. Guterres, C. Salbego, Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats, *Journal of Biomedical Nanotechnology*, 6 (2010) 694-703.

[92] S. Basavaraj, G.V. Betageri, Improved oral delivery of resveratrol using proliposomal formulation: investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol, *Expert Opinion on Drug Delivery*, 11 (2014) 493-503.

[93] I. Scognamiglio, D. De Stefano, V. Campani, L. Mayol, R. Carnuccio, G. Fabbrocini, F. Ayala, M.I. La Rotonda, G. De Rosa, Nanocarriers for topical administration of resveratrol: a comparative study, *International Journal of Pharmaceutics*, 440 (2013) 179-187.

- [94] N.K. Narayanan, D. Nargi, C. Randolph, B.A. Narayanan, Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice, *International journal of cancer. Journal International Du Cancer*, 125 (2009) 1-8.
- [95] M. Coimbra, B. Isacchi, L. van Bloois, J.S. Torano, A. Ket, X. Wu, F. Broere, J.M. Metselaar, C.J. Rijcken, G. Storm, R. Bilia, R.M. Schiffelers, Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes, *International Journal of Pharmaceutics*, 416 (2011) 433-442.
- [96] M. Sessa, M.L. Balestrieri, G. Ferrari, L. Servillo, D. Castaldo, N. D'Onofrio, F. Donsi, R. Tsao, Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems, *Food Chemistry*, 147 (2014) 42-50.
- [97] M. Sessa, R. Tsao, R. Liu, G. Ferrari, F. Donsi, Evaluation of the stability and antioxidant activity of nanoencapsulated resveratrol during in vitro digestion, *Journal of Agricultural and Food Chemistry*, 59 (2011) 12352-12360.
- [98] V. Vergaro, Y.M. Lvov, S. Leporatti, Halloysite clay nanotubes for resveratrol delivery to cancer cells, *Macromolecular Bioscience*, 12 (2012) 1265-1271.
- [99] N. Summerlin, Z. Qu, N. Pujara, Y. Sheng, S. Jambhrunkar, M. McGuckin, A. Popat, Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol, *Colloids and Surfaces. B, Biointerfaces*, 144 (2016) 1-7.

- [100] S. Karthikeyan, S.L. Hoti, N.R. Prasad, Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small cell lung cancer cells, *Biomedicine & pharmacotherapy*, 70 (2015) 274-282.
- [101] K.A. Ansari, P.R. Vavia, F. Trotta, R. Cavalli, Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study, *AAPS PharmSciTech*, 12 (2011) 279-286.
- [102] J.M. Dintaman, J.A. Silverman, Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), *Pharmaceutical Research*, 16 (1999) 1550-1556.
- [103] Z. Zhang, S. Huey Lee, S.S. Feng, Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery, *Biomaterials*, 28 (2007) 1889-1899.
- [104] M.S. Muthu, S.S. Feng, Nanopharmacology of liposomes developed for cancer therapy, *Nanomedicine (London, England)*, 5 (2010) 1017-1019.
- [105] Y. Ma, Y. Zheng, K. Liu, G. Tian, Y. Tian, L. Xu, F. Yan, L. Huang, L. Mei, Nanoparticles of Poly(Lactide-Co-Glycolide)-d-a-Tocopheryl Polyethylene Glycol 1000 Succinate Random Copolymer for Cancer Treatment, *Nanoscale Research Letters*, 5 (2010) 1161-1169.

- [106] J. Wang, R. Wang, L.B. Li, Preparation and properties of hydroxycamptothecin-loaded nanoparticles made of amphiphilic copolymer and normal polymer, *Journal of Colloid and Interface Science*, 336 (2009) 808-813.
- [107] C. Liang, Y. Yang, Y. Ling, Y. Huang, T. Li, X. Li, Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma, *Bioorganic & Medicinal Chemistry*, 19 (2011) 4057-4066.
- [108] R.J. Sokol, N. Butler-Simon, C. Conner, J.E. Heubi, F.R. Sinatra, F.J. Suchy, M.B. Heyman, J. Perrault, R.J. Rothbaum, J. Levy, et al., Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis, *Gastroenterology*, 104 (1993) 1727-1735.
- [109] L. Mu, S.S. Feng, Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol), *Journal of Controlled Release*, 80 (2002) 129-144.
- [110] S. Feng, G. Huang, Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers, *Journal of Controlled Release*, 71 (2001) 53-69.
- [111] L. Mu, S.S. Feng, PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio, *Pharmaceutical Research*, 20 (2003) 1864-1872.

- [112] L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, M. Coffin, Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability, *Pharmaceutical Research*, 16 (1999) 1812-1817.
- [113] H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, *European Journal of Cancer (Oxford, England : 1990)*, 37 (2001) 1590-1598.
- [114] A.K. Singla, A. Garg, D. Aggarwal, Paclitaxel and its formulations, *International Journal of Pharmaceutics*, 235 (2002) 179-192.
- [115] R.T. Dorr, Pharmacology and toxicology of Cremophor EL diluent, *The Annals of Pharmacotherapy*, 28 (1994) S11-14.
- [116] J.R. Fischer, K.R. Harkin, L.C. Freeman, Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs, *Veterinary therapeutics*, 3 (2002) 465-473.
- [117] L. Mu, P.-H. Seow, S.-N. Ang, S.-S. Feng, Study on surfactant coating of polymeric nanoparticles for controlled delivery of anticancer drug, *Colloid and Polymer Science*, 283 (2004) 58-65.
- [118] C. Prashant, M. Dipak, C.T. Yang, K.H. Chuang, D. Jun, S.S. Feng, Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent, *Biomaterials*, 31 (2010) 5588-5597.

- [119] S.-S. Feng, L. Zhao, Z. Zhang, G. Bhakta, K. Yin Win, Y. Dong, S. Chien, Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo, *Chemical Engineering Science*, 62 (2007) 6641-6648.
- [120] J. Moan, K. Berg, The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen, *Photochemistry and Photobiology*, 53 (1991) 549-553.
- [121] M.J. Shieh, C.Y. Hsu, L.Y. Huang, H.Y. Chen, F.H. Huang, P.S. Lai, Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells, *Journal of Controlled Release*, 152 (2011) 418-425.
- [122] R.B. Greenwald, Y.H. Choe, J. McGuire, C.D. Conover, Effective drug delivery by PEGylated drug conjugates, *Advanced Drug Delivery Reviews*, 55 (2003) 217-250.
- [123] S.S. Feng, New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?, *Nanomedicine (London, England)*, 1 (2006) 297-309.
- [124] N. Cao, S.S. Feng, Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation, *Biomaterials*, 29 (2008) 3856-3865.
- [125] K. Maruyama, Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects, *Advanced Drug Delivery Reviews*, 63 (2011) 161-169.

- [126] S. Xiong, B. Yu, J. Wu, H. Li, R.J. Lee, Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS, *Biomedicine & Pharmacotherapy*, 65 (2011) 2-8.
- [127] M.S. Muthu, S.S. Feng, Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success, *Expert Opinion on Drug Delivery*, 10 (2013) 151-155.
- [128] V.P. Torchilin, Multifunctional nanocarriers, *Advanced Drug Delivery Reviews*, 58 (2006) 1532-1555.
- [129] A.S. Abu Lila, T. Okada, Y. Doi, M. Ichihara, T. Ishida, H. Kiwada, Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?, *International Journal of Pharmaceutics*, 426 (2012) 263-270.
- [130] T. Wang, X. Yin, Y. Lu, W. Shan, S. Xiong, Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin, *International Journal of Nanomedicine*, 7 (2012) 2325-2337.
- [131] Y. Li, K. Xiao, J. Luo, J. Lee, S. Pan, K.S. Lam, A novel size-tunable nanocarrier system for targeted anticancer drug delivery, *Journal of Controlled Release*, 144 (2010) 314-323.

- [132] M.S. Muthu, S.A. Kulkarni, Y. Liu, S.S. Feng, Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats, *Nanomedicine (London, England)*, 7 (2012) 353-364.
- [133] Y. Gao, L.B. Li, G. Zhai, Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin, *Colloids and Surfaces. B, Biointerfaces*, 64 (2008) 194-199.
- [134] P. Chandrasekharan, D. Maity, C.X. Yong, K.H. Chuang, J. Ding, S.S. Feng, Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI, *Biomaterials*, 32 (2011) 5663-5672.
- [135] Y. Mi, Y. Liu, S.S. Feng, Formulation of Docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy, *Biomaterials*, 32 (2011) 4058-4066.
- [136] Z. Zhang, S.S. Feng, Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release, *Biomaterials*, 27 (2006) 262-270.
- [137] Z. Zhang, S.S. Feng, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles, *Biomaterials*, 27 (2006) 4025-4033.

- [138] Z. Zhang, S.H. Lee, C.W. Gan, S.S. Feng, In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy, *Pharmaceutical Research*, 25 (2008) 1925-1935.
- [139] Z. Zhang, S.S. Feng, Self-assembled nanoparticles of poly(lactide)--Vitamin E TPGS copolymers for oral chemotherapy, *International Journal of Pharmaceutics*, 324 (2006) 191-198.
- [140] J.M. Saul, A. Annapragada, J.V. Natarajan, R.V. Bellamkonda, Controlled targeting of liposomal doxorubicin via the folate receptor in vitro, *Journal of Controlled Release*, 92 (2003) 49-67.
- [141] X. Zhao, H. Li, R.J. Lee, Targeted drug delivery via folate receptors, *Expert Opinion on Drug Delivery*, 5 (2008) 309-319.
- [142] J.F. Ross, P.K. Chaudhuri, M. Ratnam, Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications, *Cancer*, 73 (1994) 2432-2443.
- [143] J. Pan, S.S. Feng, Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles, *Biomaterials*, 29 (2008) 2663-2672.
- [144] C.W. Gan, S.S. Feng, Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier, *Biomaterials*, 31 (2010) 7748-7757.

- [145] W.M. Pardridge, Drug targeting to the brain, *Pharmaceutical Research*, 24 (2007) 1733-1744.
- [146] B.E. Cohen, A.D. Bangham, Diffusion of Small Non-Electrolytes across Liposome Membranes, *Nature*, 236 (1972) 173-174.
- [147] K. Bogman, Y. Zysset, L. Degen, G. Hopfgartner, H. Gutmann, J. Alsenz, J. Drewe, P-glycoprotein and surfactants: effect on intestinal talinolol absorption, *Clinical Pharmacology and Therapeutics*, 77 (2005) 24-32.
- [148] A.R. Jones, E.V. Shusta, Blood-brain barrier transport of therapeutics via receptor-mediation, *Pharmaceutical Research*, 24 (2007) 1759-1771.
- [149] E. Wagner, D. Curiel, M. Cotten, Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis, *Advanced Drug Delivery Reviews*, 14 (1994) 113-135.
- [150] J. Zhao, Y. Mi, Y. Liu, S.S. Feng, Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend, *Biomaterials*, 33 (2012) 1948-1958.
- [151] K. Briley-Saebo, A. Bjornerud, D. Grant, H. Ahlstrom, T. Berg, G.M. Kindberg, Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging, *Cell and Tissue Research*, 316 (2004) 315-323.

- [152] X. Wu, H. Liu, J. Liu, K.N. Haley, J.A. Treadway, J.P. Larson, N. Ge, F. Peale, M.P. Bruchez, Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots, *Nature Biotechnology*, 21 (2003) 41-46.
- [153] Y.A. Wang, J.J. Li, H. Chen, X. Peng, Stabilization of inorganic nanocrystals by organic dendrons, *Journal of the American Chemical Society*, 124 (2002) 2293-2298.
- [154] J. Pan, Y. Wang, S.S. Feng, Formulation, characterization, and in vitro evaluation of quantum dots loaded in poly(lactide)-vitamin E TPGS nanoparticles for cellular and molecular imaging, *Biotechnology and Bioengineering*, 101 (2008) 622-633.
- [155] R.K. Jain, Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function, *Journal of Controlled Release*, 74 (2001) 7-25.
- [156] J. Pan, S.S. Feng, Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers, *Biomaterials*, 30 (2009) 1176-1183.
- [157] Y.F. Tan, P. Chandrasekharan, D. Maity, C.X. Yong, K.H. Chuang, Y. Zhao, S. Wang, J. Ding, S.S. Feng, Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles, *Biomaterials*, 32 (2011) 2969-2978.
- [158] R. Wang, R. Xiao, Z. Zeng, L. Xu, J. Wang, Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives

as nanomaterials in drug delivery, *International Journal of Nanomedicine*, 7 (2012) 4185-4198.

[159] N. Bertrand, J. Wu, X. Xu, N. Kamaly, O.C. Farokhzad, Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology, *Advanced Drug Delivery Reviews*, 66 (2014) 2-25.

[160] G. Wang, J. Wang, W. Wu, S.S. Tony To, H. Zhao, J. Wang, Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs, *Expert Opinion on Drug Delivery*, 12 (2015) 1475-1499.

[161] A.S. Abu Lila, N.E. Eldin, M. Ichihara, T. Ishida, H. Kiwada, Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: A possible mechanism and the potential for clinical application, *International Journal of Pharmaceutics*, 438 (2012) 176-183.

[162] S. Hak, H.M. Sanders, P. Agrawal, S. Langereis, H. Grull, H.M. Keizer, F. Arena, E. Terreno, G.J. Strijkers, K. Nicolay, A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging, *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V*, 72 (2009) 397-404.

[163] D.K. Wang, C.X. Zhang, W.T. Zhang, C.H. Zhao, S.X. Guan, Characteristics and pharmacokinetics of docetaxel liposome containing Tween 80 or PEG-DSPE, *Journal of Drug Delivery Science and Technology*, 18 (2008) 253-257.

- [164] G. He, L.L. Ma, J. Pan, S. Venkatraman, ABA and BAB type triblock copolymers of PEG and PLA: a comparative study of drug release properties and "stealth" particle characteristics, *International Journal of Pharmaceutics*, 334 (2007) 48-55.
- [165] Y. Dong, S.S. Feng, Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs, *Biomaterials*, 25 (2004) 2843-2849.
- [166] K. Hu, J. Li, Y. Shen, W. Lu, X. Gao, Q. Zhang, X. Jiang, Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations, *Journal of Controlled Release*, 134 (2009) 55-61.
- [167] S.S. Venkatraman, P. Jie, F. Min, B.Y. Freddy, G. Leong-Huat, Micelle-like nanoparticles of PLA-PEG-PLA triblock copolymer as chemotherapeutic carrier, *International Journal of Pharmaceutics*, 298 (2005) 219-232.
- [168] R. Kunii, H. Onishi, Y. Machida, Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin, *European Journal of Pharmaceutics and Biopharmaceutics*, 67 (2007) 9-17.
- [169] S. Essa, J.M. Rabanel, P. Hildgen, Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density, *International Journal of Pharmaceutics*, 411 (2011) 178-187.

- [170] L. Xiao, X. Xiong, X. Sun, Y. Zhu, H. Yang, H. Chen, L. Gan, H. Xu, X. Yang, Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles, *Biomaterials*, 32 (2011) 5148-5157.
- [171] Z. Zhang, X. Xiong, J. Wan, L. Xiao, L. Gan, Y. Feng, H. Xu, X. Yang, Cellular uptake and intracellular trafficking of PEG-b-PLA polymeric micelles, *Biomaterials*, 33 (2012) 7233-7240.
- [172] C.Y. Zhang, Y.Q. Yang, T.X. Huang, B. Zhao, X.D. Guo, J.F. Wang, L.J. Zhang, Self-assembled pH-responsive MPEG-b-(PLA-co-PAE) block copolymer micelles for anticancer drug delivery, *Biomaterials*, 33 (2012) 6273-6283.
- [173] Z.X. Zhao, S.Y. Gao, J.C. Wang, C.J. Chen, E.Y. Zhao, W.J. Hou, Q. Feng, L.Y. Gao, X.Y. Liu, L.R. Zhang, Q. Zhang, Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery, *Biomaterials*, 33 (2012) 6793-6807.
- [174] G. Singh, R.S. Pai, V. Pandit, Development and validation of a HPLC method for the determination of trans-resveratrol in spiked human plasma, *Journal of Advanced Pharmaceutical Technology and Research*, 3 (2012) 130-135.
- [175] A.K. Kushwaha, P.R. Vuddanda, P. Karunanidhi, S.K. Singh, S. Singh, Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability, *BioMed Research International*, 2013 (2013) 584549.

- [176] N. Csaba, A. Sánchez, M.J. Alonso, PLGA: Poloxamer and PLGA: Poloxamine blend nanostructures as carriers for nasal gene delivery, *Journal of Controlled Release*, 113 (2006) 164-172.
- [177] P. Zhao, M. Zheng, C. Yue, Z. Luo, P. Gong, G. Gao, Z. Sheng, C. Zheng, L. Cai, Improving drug accumulation and photothermal efficacy in tumor depending on size of ICG loaded lipid-polymer nanoparticles, *Biomaterials*, 35 (2014) 6037-6046.
- [178] Z. Wang, P.C. Ho, Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities, *Small (Weinheim an der Bergstrasse, Germany)*, 6 (2010) 2576-2583.
- [179] L. Zhang, J.M. Chan, F.X. Gu, J.W. Rhee, A.Z. Wang, A.F. Radovic-Moreno, F. Alexis, R. Langer, O.C. Farokhzad, Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform, *ACS Nano*, 2 (2008) 1696-1702.
- [180] G. Pasut, D. Paolino, C. Celia, A. Mero, A.S. Joseph, J. Wolfram, D. Cosco, O. Schiavon, H. Shen, M. Fresta, Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy, *Journal of Controlled Release*, 199 (2015) 106-113.
- [181] E.H. Siemann, L.L. Creasy, Concentration of the Phytoalexin Resveratrol in Wine, *American Journal of Enology and Viticulture*, 43 (1992) 49-52.

- [182] P.R. Vuddanda, V.M. Rajamanickam, M. Yaspal, S. Singh, Investigations on Agglomeration and Haemocompatibility of Vitamin E TPGS Surface Modified Berberine Chloride Nanoparticles, *BioMed Research International*, 2014 (2014) 11.
- [183] B. Singh, P.R. Vuddanda, R.V. M, V. Kumar, P.S. Saxena, S. Singh, Cefuroxime axetil loaded solid lipid nanoparticles for enhanced activity against *S. aureus* biofilm, *Colloids and Surfaces. B, Biointerfaces*, 121 (2014) 92-98.
- [184] S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, R.K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, *Proceedings of the National Academy of Sciences of the United States of America*, 95 (1998) 4607-4612.
- [185] C. Constantinou, C.M. Neophytou, P. Vraka, J.A. Hyatt, K.A. Papas, A.I. Constantinou, Induction of DNA damage and caspase-independent programmed cell death by vitamin E, *Nutrition and Cancer*, 64 (2012) 136-152.
- [186] C.M. Neophytou, A.I. Constantinou, Drug Delivery Innovations for Enhancing the Anticancer Potential of Vitamin E Isoforms and Their Derivatives, *BioMed Research International*, 2015 (2015) 16.
- [187] C.M. Neophytou, C. Constantinou, P. Papageorgis, A.I. Constantinou, D-alpha-tocopheryl polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis selectively in Survivin-overexpressing breast cancer cells, *Biochemical Pharmacology*, 89 (2014) 31-42.

- [188] H.J. Youk, E. Lee, M.K. Choi, Y.J. Lee, J.H. Chung, S.H. Kim, C.H. Lee, S.J. Lim, Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol, *Journal of Controlled Release*, 107 (2005) 43-52.
- [189] K. Amin, R.M. Dannenfelser, In vitro hemolysis: guidance for the pharmaceutical scientist, *Journal of Pharmaceutical Sciences*, 95 (2006) 1173-1176.
- [190] M.E. Juan, E. Gonzalez-Pons, J.M. Planas, Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats, *The Journal of nutrition*, 140 (2010) 489-495.
- [191] J. Kreuter, Nanoparticulate systems for brain delivery of drugs, *Advanced Drug Delivery Reviews*, 47 (2001) 65-81.
- [192] J. Kreuter, Application of nanoparticles for the delivery of drugs to the brain, *International Congress Series*, 1277 (2005) 85-94.
- [193] J. Kreuter, R.N. Alyautdin, D.A. Kharkevich, A.A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), *Brain Research*, 674 (1995) 171-174.
- [194] L. Costantino, G. Tosi, B. Ruozi, L. Bondioli, M.A. Vandelli, F. Forni, Chapter 3 - Colloidal systems for CNS drug delivery, in: S. Hari Shanker (Ed.) *Progress in Brain Research*, Elsevier, 2009, pp. 35-69.
- [195] H. Zhu, H. Chen, X. Zeng, Z. Wang, X. Zhang, Y. Wu, Y. Gao, J. Zhang, K. Liu, R. Liu, L. Cai, L. Mei, S.S. Feng, Co-delivery of chemotherapeutic drugs with vitamin E

TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance, *Biomaterials*, 35 (2014) 2391-2400.

[196] J.M. Chan, L. Zhang, K.P. Yuet, G. Liao, J.W. Rhee, R. Langer, O.C. Farokhzad, PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery, *Biomaterials*, 30 (2009) 1627-1634.

[197] Y. Zheng, B. Yu, W. Weecharangsan, L. Piao, M. Darby, Y. Mao, R. Koynova, X. Yang, H. Li, S. Xu, L.J. Lee, Y. Sugimoto, R.W. Brueggemeier, R.J. Lee, Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells, *International Journal of Pharmaceutics*, 390 (2010) 234-241.

[198] C.J. Cheng, W.M. Saltzman, Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides, *Biomaterials*, 32 (2011) 6194-6203.

[199] J.M. Chan, J.-W. Rhee, C.L. Drum, R.T. Bronson, G. Golomb, R. Langer, O.C. Farokhzad, In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles, *Proceedings of the National Academy of Sciences*, 108 (2011) 19347-19352.

[200] C. Clawson, L. Ton, S. Aryal, V. Fu, S. Esener, L. Zhang, Synthesis and Characterization of Lipid-Polymer Hybrid Nanoparticles with pH-Triggered Poly(ethylene glycol) Shedding, *Langmuir*, 27 (2011) 10556-10561.

- [201] S.D. Kong, M. Sartor, C.M. Hu, W. Zhang, L. Zhang, S. Jin, Magnetic field activated lipid-polymer hybrid nanoparticles for stimuli-responsive drug release, *Acta Biomaterialia*, 9 (2013) 5447-5452.
- [202] P.M. Valencia, P.A. Basto, L. Zhang, M. Rhee, R. Langer, O.C. Farokhzad, R. Karnik, Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing, *ACS Nano*, 4 (2010) 1671-1679.
- [203] A.Z. Wang, K. Yuet, L. Zhang, F.X. Gu, M. Huynh-Le, A.F. Radovic-Moreno, P.W. Kantoff, N.H. Bander, R. Langer, O.C. Farokhzad, ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation, *Nanomedicine (London, England)*, 5 (2010) 361-368.
- [204] E. Afergan, H. Epstein, R. Dahan, N. Koroukhov, K. Rohekar, H.D. Danenberg, G. Golomb, Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes, *Journal of Controlled Release*, 132 (2008) 84-90.
- [205] W. Lv, J. Guo, J. Li, L. Huang, Q. Ping, Distribution of liposomal breviscapine in brain following intravenous injection in rats, *International Journal of Pharmaceutics*, 306 (2005) 99-106.
- [206] D. Cosco, D. Paolino, J. Maiuolo, L.D. Marzio, M. Carafa, C.A. Ventura, M. Fresta, Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery, *International Journal of Pharmaceutics*, 489 (2015) 1-10.

- [207] P.G. Cadena, M.A. Pereira, R.B.S. Cordeiro, I.M.F. Cavalcanti, B. Barros Neto, M.d.C.C.B. Pimentel, J.L. Lima Filho, V.L. Silva, N.S. Santos-Magalhães, Nanoencapsulation of quercetin and resveratrol into elastic liposomes, *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 1828 (2013) 309-316.
- [208] M.W. Joraholmen, N. Skalko-Basnet, G. Acharya, P. Basnet, Resveratrol-loaded liposomes for topical treatment of the vaginal inflammation and infections, *European Journal of Pharmaceutical Sciences : official journal of the European Federation for Pharmaceutical Sciences*, 79 (2015) 112-121.
- [209] E.A. Bender, M.D. Adorne, L.M. Colome, D.S. Abdalla, S.S. Guterres, A.R. Pohlmann, Hemocompatibility of poly(ϵ -caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan, *International Journal of Pharmaceutics*, 426 (2012) 271-279.
- [210] D.E. Owens, N.A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, *International Journal of Pharmaceutics*, 307 (2006) 93-102.
- [211] J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging and therapy, *Nanomedicine (London, England)*, 6 (2011) 715-728.
- [212] W.-H. Hsu, S.-Y. Liu, Y.-J. Chang, A.-J. Long, C.-H. Chang, T.-W. Lee, Strategy for reducing liver uptake of ^{188}Re -liposome by pretreating PEGylated liposomal doxorubicin, *Journal of Nuclear Medicine*, 53 (2012) 1206.

[213] F. Atyabi, A. Farkhondehfar, F. Esmaili, R. Dinarvand, Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice, *Acta Pharmaceutica (Zagreb, Croatia)*, 59 (2009) 133-144.

[214] T.-H. Chow, Y.-Y. Lin, J.-J. Hwang, H.-E. Wang, Y.-L. Tseng, S.-J. Wang, R.-S. Liu, W.-J. Lin, C.-S. Yang, G. Ting, Improvement of Biodistribution and Therapeutic Index via Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/luc Xenografted Mouse Model, *Anticancer Research*, 29 (2009) 2111-2120.